Cornerstone Financial Management
MAZE icon

Cornerstone Financial Management’s Maze Therapeutics MAZE Stock Holding History

Cornerstone Financial Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$761 Hold
28
– – ﹤0.01% 1270
2026
Q2 		$836 Hold
28
– – ﹤0.01% 1167
2026
Q1 		$836 Hold
28
– – ﹤0.01% 1033
2025
Q4 		$1.16K Buy
+28
New +$962 ﹤0.01% 873

Other funds holding MAZE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Cornerstone Financial Management's MAZE Position: Q3 2026 in Review

Cornerstone Financial Management held its Maze Therapeutics (MAZE) position steady in Q3 2026 at 28 shares worth $761. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

Cornerstone Financial Management first reported a position in MAZE in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.16K in Q4 2025. 95 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Cornerstone Financial Management held 28 shares of Maze Therapeutics worth $761 as of Q3 2026.
  • Cornerstone Financial Management left its Maze Therapeutics share count unchanged in Q3 2026.
  • Maze Therapeutics made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q3 2026, its #1270 holding.
  • Cornerstone Financial Management first reported a position in Maze Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Cornerstone Financial Management's Maze Therapeutics position peaked at $1.16K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Cornerstone Financial Management's 13F filing for Q3 2026, filed 10 Nov 2026.